A detailed history of Kynam Capital Management, LP transactions in Natera, Inc. stock. As of the latest transaction made, Kynam Capital Management, LP holds 2,042,471 shares of NTRA stock, worth $332 Million. This represents 21.3% of its overall portfolio holdings.

Number of Shares
2,042,471
Previous 2,014,408 1.39%
Holding current value
$332 Million
Previous $218 Million 19.01%
% of portfolio
21.3%
Previous 16.98%

Shares

11 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$97.75 - $129.67 $2.74 Million - $3.64 Million
28,063 Added 1.39%
2,042,471 $260 Million
Q2 2024

Aug 14, 2024

BUY
$85.28 - $112.6 $1.23 Million - $1.62 Million
14,408 Added 0.72%
2,014,408 $218 Million
Q1 2024

May 15, 2024

SELL
$59.21 - $92.9 $23.7 Million - $37.2 Million
-400,000 Reduced 16.67%
2,000,000 $183 Million
Q4 2023

Feb 14, 2024

SELL
$37.55 - $62.64 $22.7 Million - $37.8 Million
-603,668 Reduced 20.1%
2,400,000 $150 Million
Q3 2023

Nov 14, 2023

BUY
$43.4 - $62.52 $4.5 Million - $6.48 Million
103,668 Added 3.57%
3,003,668 $133 Million
Q2 2023

Aug 14, 2023

SELL
$47.08 - $55.16 $858,597 - $1.01 Million
-18,237 Reduced 0.62%
2,900,000 $141 Million
Q1 2023

May 15, 2023

BUY
$36.57 - $58.29 $11.5 Million - $18.4 Million
315,030 Added 12.1%
2,918,237 $162 Million
Q4 2022

Feb 14, 2023

BUY
$34.17 - $47.91 $20 Million - $28 Million
584,847 Added 28.98%
2,603,207 $105 Million
Q3 2022

Nov 14, 2022

BUY
$36.93 - $56.68 $28.8 Million - $44.2 Million
779,313 Added 62.9%
2,018,360 $88.4 Million
Q2 2022

Aug 15, 2022

BUY
$28.13 - $44.54 $7.67 Million - $12.1 Million
272,647 Added 28.21%
1,239,047 $43.9 Million
Q1 2022

May 13, 2022

BUY
$30.32 - $91.33 $29.3 Million - $88.3 Million
966,400 New
966,400 $39.3 Million

Others Institutions Holding NTRA

About Natera, Inc.


  • Ticker NTRA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Diagnostics & Research
  • Shares Outstandng 96,957,400
  • Market Cap $15.7B
  • Description
  • Natera, Inc., a diagnostics company, develops and commercializes molecular testing services worldwide. It offers Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus with a blood draw from the mother, as well as twin pregnancies for zygosity; Vistara, a single-gene mutations screening test to identify sing...
More about NTRA
Track This Portfolio

Track Kynam Capital Management, LP Portfolio

Follow Kynam Capital Management, LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Kynam Capital Management, LP, based on Form 13F filings with the SEC.

News

Stay updated on Kynam Capital Management, LP with notifications on news.